Guangzhou Sun Yat-sen University Embraces Secarna Pharmaceuticals’ ‘Next Generation’ Antisense Oligonucleotide Platform for COVID-19

Guangzhou Sun Yat-sen University Embraces Secarna Pharmaceuticals’ ‘Next Generation’ Antisense Oligonucleotide Platform for COVID-19

A Munich-based biotech venture called Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”) focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAPlus™...

Pin It on Pinterest